Welcome to our dedicated page for Ocuphire Pharma SEC filings (Ticker: OCUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OCUP SEC filings page on Stock Titan provides access to the historical regulatory record for Ocuphire Pharma, Inc., which later combined with Opus Genetics, Inc. and was renamed Opus Genetics. After the transaction, SEC reports identify the registrant as Opus Genetics, Inc., but they remain part of the continuous filing history linked to the former Nasdaq ticker OCUP and the current ticker "IRD."
Through this archive, readers can review current and historical reports that describe the company’s evolution from a clinical-stage ophthalmic biopharmaceutical developer of small-molecule therapies to a combined entity with a pipeline that includes adeno-associated virus-based gene therapies for inherited retinal diseases. Filings such as Forms 8-K detail material events including funding agreements for specific gene therapy programs, changes in executive leadership, private placements of common stock, and collaboration arrangements with organizations like the Foundation Fighting Blindness Retinal Degeneration Fund and other funding parties.
Investors interested in the development of APX3330 for non-proliferative diabetic retinopathy and Phentolamine Ophthalmic Solution 0.75% for presbyopia, dim light disturbances, and pharmacologically induced mydriasis can use the filings to trace clinical and regulatory milestones, license terms with commercial partners, and disclosures about expected cash runway. As the company transitioned to Opus Genetics, additional filings describe its focus on gene therapies for conditions such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa.
On Stock Titan, these SEC documents are updated from EDGAR and can be paired with AI-powered summaries that explain key points in plain language. Users can quickly scan 8-Ks for material agreements, capital raises, and leadership changes, and follow how historical OCUP programs and obligations carry forward into the Opus Genetics era under the IRD ticker.
Robert E. Gagnon, Chief Financial Officer and Director of Opus Genetics, Inc., reported two equity grants to himself. The filing shows a grant of 200,000 restricted stock units on September 10, 2025 that vest 25% on September 2, 2026 with the remainder vesting monthly over the next 36 months, subject to continued service. It also shows an employee stock option granted on September 2, 2025 to purchase 250,000 shares at an exercise price of $1.23; the option will vest 25% on September 2, 2026 with the remainder vesting monthly over 36 months and shows an expiration/related date of September 1, 2035. Following these grants, the reporter beneficially owned 200,000 common shares from the RSUs and 250,000 underlying shares from the option, each reported as direct ownership. The form is signed by a power of attorney on behalf of the reporting person on September 11, 2025.
Robert E. Gagnon, listed at C/O Opus Genetics, Inc., filed an Initial Form 3 reporting his relationship to the issuer as a director and Chief Financial Officer. The event date is 09/02/2025. The filing states no securities are beneficially owned and includes Exhibit 24 (Power of Attorney). The form was signed by Amy Rabourn by power of attorney on 09/11/2025.
Opus Genetics, Inc. filed a Registration Statement on Form S-8 dated September 10, 2025 to register securities under an employee benefit plan. The filing incorporates by reference the companys 2024 Annual Report (filed March 31, 2025), quarterly reports filed May 15 and August 13, 2025, numerous Form 8-Ks through September 2, 2025, and the Form 8-A description of common stock. The filing lists exhibits and includes a power of attorney and officer and director signatures authorizing the submission.
Opus Genetics, Inc. reported that it has appointed Robert Gagnon as Chief Financial Officer and principal accounting officer, effective September 2, 2025. He will receive an annual base salary of $465,000 and will be eligible for an annual performance bonus of up to 45% of his base salary.
As part of his package, Opus Genetics will grant Mr. Gagnon a stock option for 250,000 shares of common stock and a separate award for 200,000 shares, each vesting over four years under the company’s 2021 Inducement Plan. The company states there are no arrangements with other persons relating to his selection, no family relationships with current leadership, and no related-party transactions requiring disclosure. Mr. Gagnon brings prior CFO and senior finance experience from several life sciences and healthcare companies.
Opus Genetics, Inc. director Gallagher Cam reported a purchase of 869,565 shares of the issuer's common stock on 08/25/2025 at a price of $1.15 per share. After the transaction the reporting person beneficially owned 1,810,430 shares. The Form 4 was submitted by power of attorney on 08/27/2025.
Opus Genetics, Inc. director Sean Ainsworth reported an open-market purchase of 86,956 shares of the company's common stock on 08/25/2025 at a price of $1.15 per share, increasing his beneficial ownership to 254,818 shares. The Form 4 was signed via power of attorney on 08/27/2025. The filing shows no reported derivative transactions.
Opus Genetics, Inc. disclosed a private placement financing in which it agreed to issue and sell 3,138,338 shares of common stock, raising approximately $3.5 million in gross proceeds. The transaction closed on August 25, 2025 and involved certain investors led by board chair Cam Gallagher, who invested $1.0 million, alongside lead independent director Sean Ainsworth and other participants.
The company plans to use the net proceeds to expedite manufacturing process development, including scaling up clinical and commercial production and testing to secure sufficient cGMP material for its gene therapy candidates OPGx-LCA5 and OPGx-BEST1. The shares were sold without underwriting discounts or commissions and were issued in reliance on private offering exemptions under Section 4(a)(2) and/or Regulation D of the Securities Act.
Opus Genetics, Inc. disclosed that Nantahala Capital Management, LLC and two individuals associated with it each may be deemed the beneficial owner of 6,250,299 shares of the company’s common stock, representing 9.99% of the class. The reported total includes 2,904,378 shares that may be acquired within 60 days upon exercise of warrants, and all reported shares are held with shared voting and dispositive power (no sole voting or dispositive power). The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control. A fund advised by Nantahala, Blackwell Partners LLC - Series A, has the right to receive dividends or sale proceeds for more than 5% of the reported shares.
Opus Genetics, Inc. reported license and collaboration revenue of $2.882 million for the quarter and $7.252 million for the six months, up from $1.112 million and $2.823 million a year earlier. Operating expenses rose to $11.8 million in the quarter (research and development $6.0 million; general and administrative $5.8 million), producing a net loss of $7.42 million for the quarter and $15.614 million for the six-month period, with basic and diluted loss per share of $(0.12) and $(0.32), respectively.
The balance sheet shows $32.4 million in cash and cash equivalents and total assets of $38.7 million. Total liabilities were $21.2 million, including $11.8 million of warrant liabilities recorded in connection with March 2025 financings that produced combined gross proceeds of approximately $21.5 million. The Company had 59,908,055 shares outstanding as of the reported count and states its current cash is sufficient to fund planned expenditures for at least twelve months. The filing discloses sizeable potential milestone obligations under acquired licenses (including maximums of $111.7 million, $76.4 million and $93.5 million for certain agreements) that were not recorded because they were not deemed probable.
Opus Genetics, Inc. reported that on August 13, 2025 it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and the company also furnished a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.1. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act or incorporated by reference except by specific reference in a later filing. The report shows Opus Genetics is a Delaware corporation and lists its common stock trading under the ticker IRD on Nasdaq. The document is signed by Dr. George Magrath, Chief Executive Officer.